Johnson & Johnson

JNJ

Market cap $460B

Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.

Johnson & Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

We narrowly escaped a sustained stock meltdown this year. In April, the S&P 500 briefly sank into bear-market territory due to investors' fears about the impact of President Donald Trump's tariffs on corporate profits and the broader economy.

Bank of America maintained a ‘Neutral' rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and hinted at a strategic MedTech shake-up. In a note Wednesday, the bank highlighted that J&J's third-quarter revenue and earnings per share beat consensus by roughly 1%, driven largely by stronger-than-expected performance from its Stelara biologic.

Johnson & Johnson's NYSE: JNJ stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare businesses to focus on higher-margin, more potent growth markets.

Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a standalone company.

Johnson & Johnson (JNJ -0.02%) is one of the world's best dividend stocks. The healthcare giant has increased its dividend payment for 63 consecutive years.

Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.'

J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.